Carmichael Group - Leukaemia modelling

Leukaemia modelling and therapeutic discovery group

Key Terms

Leukaemia, Haematopoiesis, Erythroid Cell Biology, Genetics, Mouse Models

Research Goal

Acute Myeloid Leukaemia (AML) is a genetically heterogeneous malignancy that continues to have a poor overall survival rate despite extensive research in this area. While chemotherapeutic regimens are effective in inducing complete remission in approximately 70% of patients younger than 60 years of age, more than 40% of all AML patients will ultimately succumb to relapsed or therapeutically refractory disease. The Carmichael group aims to use in vivo and in vitro genetic models of AML to identify common molecular and biological dependencies of transformed myeloid cells, which may represent novel therapeutic targets with broad applicability across diverse genetic subtypes.

Honours and postgraduate research Projects

Group Leader -  Dr Catherine Carmichael

Catherine Carmichael Dr Catherine Carmichael's research focuses on gaining an understanding of the molecular mechanisms driving Acute Myeloid Leukaemia (AML) development and pathogenesis; with the ultimate goal of identifying novel methods for therapeutically targeting this extremely poor outcome malignancy.

Find out more about Dr Catherine Carmichael

Current Research Overview

Our current research focuses on Acute Erythroid Leukaemia (AEL), which is a particularly aggressive and poorly understood subtype of AML that targets the red blood cell lineage. We have recently contributed to the world’s first complete genomic characterisation of AEL, and now have a unique understanding of the genetic lesions that define this malignancy. Through the generation of in vivo and in vitro genetic models that faithfully recapitulate the mutational landscape of human AEL, we aim to shed light on the mechanisms driving erythroid transformation and identify novel therapeutic strategies for patients with this disease.

Projects and Opportunities

  • Investigation of ETS-transcription factor function during normal and aberrant red blood cell development
  • Generation of genetic models of Acute Erythroid Leukaemia
  • Generation and characterisation of iPS cells from Acute Leukaemia patient samples

Selected Publications

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, De Mazière C, Milne A, Samuel S, Gillinder KR, Hediyeh-Zadeh S, Vo ANQ, Huang Y, Knezevic K, McInnes WRL, Shields BJ, Mitchell H, Ritchie ME, Lammens T, Lintermans B, Van Vlierberghe P, Wong N, Haigh K, Thoms JAI, Toulmin E, Curtis DJ, Oxley EP, Dickins RA, Beck D, Perkins AC, McCormack MP, Davis MJ, Berx G, Zuber J, Pimanda JE, Kile BT, Goossens S, Haigh JJ. Blood. 2020 May 5. doi: 10.1182/blood.2019002548. [Epub ahead of print]